Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2020.11818
Abstract: Importance Robust predictors for response to anti-programmed death 1 and its ligand (PD-1/PD-L1) immunotherapy in non-small cell lung cancer (NSCLC) are not fully characterized. Objective To evaluate whether PD-L1 (CD274) copy number gains (CNGs), comprising… read more here.
Keywords: nivolumab monotherapy; response; response nivolumab; programmed death ... See more keywords
Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.4208
Abstract: Despite improvements in the management of renal cell carcinomas (RCC) with the advent of immunotherapy, only a few patients respond to these treatments. Predictors of response to nivolumab are currently being investigated but are still… read more here.
Keywords: response nivolumab; renal cell; management renal;
Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-017-1118-x
Abstract: BackgroundCurrently, no markers predictive of response to nivolumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) are currently recognized in Japan. The present study was undertaken to identify such markers.Materials and methodsMedical records… read more here.
Keywords: treatment immediately; nivolumab monotherapy; response; response nivolumab ... See more keywords
Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.7_suppl.5
Abstract: 6050Background: Nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody, demonstrated longer median overall survival (7.5 vs 5.1 months) and improved response (13.3% vs 5.8%) versus invest... read more here.
Keywords: potential predictive; response; biomarkers response; response nivolumab ... See more keywords